The Board of Eliem Therapeutics, Inc. has approved a corporate reorganization plan to conserve financial resources. As part of the reorganization, the Company will reduce its workforce by approximately 55% in the first half of 2023. In connection with this reorganization, Erin Lavelle, chief financial officer will depart the Company following a short transition period.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.48 USD | +1.72% | +13.35% | +252.22% |
11/04 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
11/04 | Top Midday Gainers | MT |
1st Jan change | Capi. | |
---|---|---|
+252.22% | 261M | |
+2.72% | 108B | |
+10.23% | 105B | |
+1.57% | 23.46B | |
-12.19% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-7.22% | 17.19B | |
+6.15% | 13.99B | |
+35.85% | 12.53B |
- Stock Market
- Equities
- ELYM Stock
- News Eliem Therapeutics, Inc.
- Erin Lavelle to Depart as Chief Financial Officer of Eliem Therapeutics, Inc